(Z)2-(5-(4-methoxybenzylidene)-2, 4-dioxothiazolidin-3-yl) acetic acid protects rats from CCl4-induced liver injury

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 5, 2012, Pages 966-973

  Wang, Zhen ling ^a   Deng, Chong yang ^a   Zheng, Hao ^a   Xie, Cai feng ^a   Wang, Xian huo ^a   Luo, You fu ^a   Chen, Zhi zhi ^a   Cheng, Ping ^a   Chen, Li Juan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Aldose reductase; Hepatitis; Liver fibrosis; Macrophages

Indexed keywords

2 [5 (4 METHOXYBENZYLIDENE) 2, 4 DIOXOTHIAZOLIDIN 3 YL]ACETIC ACID; ALANINE AMINOTRANSFERASE; ALDOSE REDUCTASE INHIBITOR; ANTIINFLAMMATORY AGENT; CARBON TETRACHLORIDE; GLUTATHIONE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; FIBROGENESIS; IN VIVO STUDY; LIVER FIBROSIS; LIVER INJURY; LIVER LEVEL; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

EID: 84860255772     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06913.x     Document Type: Article

References (38)

1. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 2000; 275: 2247-50.
2. Duffield JS, Forbes SJ, Constandinou CM etal. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Invest. 2005; 115: 56-65.
3. Bataller R, Brenner DA. Liver fibrosis. J. Clin. Invest. 2005; 115: 209-18.
4. Wheeler MD, Yamashina S, Froh M, Rusyn I, Thurman RG. Adenoviral gene delivery can inactivate Kupffer cells: role of oxidants in NF-kappaB activation and cytokine production. J. Leukoc. Biol. 2001; 69: 622-30.
5. Baldwin AS, Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 1996; 14: 649-83.
6. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu. Rev. Cell Biol. 1994; 10: 405-55.
7. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996; 87: 13-20.
8. Cimino F, Esposito F, Ammendola R, Russo T. Gene regulation by reactive oxygen species. Curr. Top. Cell. Regul. 1997; 35: 123-48.
9. Tammali R, Ramana KV, Singhal SS, Awasthi S, Srivastava SK. Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells. Cancer Res. 2006; 66: 9705-13.
10. Yadav UC, Srivastava SK, Ramana KV. Aldose reductase inhibition prevents endotoxin-induced uveitis in rats. Invest. Ophthalmol. Vis. Sci. 2007; 48: 4634-42.
11. Yadav UC, Naura AS, Aguilera-Aguirre L etal. Aldose reductase inhibition suppresses the expression of Th2 cytokines and airway inflammation in ovalbumin-induced asthma in mice. J. Immunol. 2009; 183: 4723-32.
12. Alexiou P, Pegklidou K, Chatzopoulou M, Nicolaou I, Demopoulos VJ. Aldose reductase enzyme and its implication to major health problems of the 21(st) century. Curr. Med. Chem. 2009; 16: 734-52.
13. Ramana KV, Fadl AA, Tammali R, Reddy AB, Chopra AK, Srivastava SK. Aldose reductase mediates the lipopolysaccharide-induced release of inflammatory mediators in RAW264.7 murine macrophages. J. Biol. Chem. 2006; 281: 33019-29.
14. Ravindranath TM, Mong PY, Ananthakrishnan R etal. Novel role for aldose reductase in mediating acute inflammatory responses in the lung. J. Immunol. 2009; 183: 8128-37.
15. Ramana KV, Willis MS, White MD etal. Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition. Circulation 2006; 114: 1838-46.
16. Maccari R, Ciurleo R, Giglio M etal. Identification of new non-carboxylic acid containing inhibitors of aldose reductase. Bioorg. Med. Chem. 2010; 18: 4049-55.
17. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J. Nutr. 2004; 134: 489-92.
18. Leclercq IA, Sempoux C, Starkel P, Horsmans Y. Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats. Gut 2006; 55: 1020-9.
19. Marra F. Chemokines in liver inflammation and fibrosis. Front. Biosci. 2002; 7: d1899-914.
20. Williams AS, Topley N, Dojcinov S, Richards PJ, Williams BD. Amelioration of rat antigen-induced arthritis by liposomally conjugated methotrexate is accompanied by down-regulation of cytokine mRNA expression. Rheumatology (Oxford). 2001; 40: 375-83.
21. Hentze H, Gantner F, Kolb SA, Wendel A. Depletion of hepatic glutathione prevents death receptor-dependent apoptotic and necrotic liver injury in mice. Am. J. Pathol. 2000; 156: 2045-56.
22. Fritsche G, Dlaska M, Barton H, Theurl I, Garimorth K, Weiss G. Nramp1 functionality increases inducible nitric oxide synthase transcription via stimulation of IFN regulatory factor 1 expression. J. Immunol. 2003; 171: 1994-8.
23. Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. Liver Int. 2006; 26: 1175-86.
24. Nath J, Powledge A. Modulation of human neutrophil inflammatory responses by nitric oxide: studies in unprimed and LPS-primed cells. J. Leukoc. Biol. 1997; 62: 805-16.
25. Ramana KV, Srivastava SK. Aldose reductase: a novel therapeutic target for inflammatory pathologies. Int. J. Biochem. Cell Biol. 2009; 42: 17-20.
26. Srivastava SK, Ramana KV, Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr. Rev. 2005; 26: 380-92.
27. Ramana KV, Chandra D, Srivastava S, Bhatnagar A, Srivastava SK. Aldose reductase mediates the mitogenic signals of cytokines. Chem. Biol. Interact. 2003; 143-144: 587-96.
28. Velasco M, Diaz-Guerra MJ, Martin-Sanz P, Alvarez A, Bosca L. Rapid up-regulation of IkappaBbeta and abrogation of NF-kappaB activity in peritoneal macrophages stimulated with lipopolysaccharide. J. Biol. Chem. 1997; 272: 23025-30.
29. Edwards MJ, Keller BJ, Kauffman FC, Thurman RG. The involvement of Kupffer cells in carbon tetrachloride toxicity. Toxicol. Appl. Pharmacol. 1993; 119: 275-9.
30. Ramana KV, Srivastava SK. Mediation of aldose reductase in lipopolysaccharide-induced inflammatory signals in mouse peritoneal macrophages. Cytokine 2006; 36: 115-22.
31. Son G, Iimuro Y, Seki E, Hirano T, Kaneda Y, Fujimoto J. Selective inactivation of NF-kappaB in the liver using NF-kappaB decoy suppresses CCl4-induced liver injury and fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2007; 293: G631-9.
32. Perez Tamayo R. Is cirrhosis of the liver experimentally produced by CCl4 and adequate model of human cirrhosis? Hepatology 1983; 3: 112-20.
33. Bissell DM, Roulot D, George J. Transforming growth factor beta and the liver. Hepatology 2001; 34: 859-67.
34. Parsons CJ, Takashima M, Rippe RA. Molecular mechanisms of hepatic fibrogenesis. J. Gastroenterol. Hepatol. 2007; 22: S79-84.
35. Nagarajan RP, Chen F, Li W etal. Repression of transforming-growth-factor-beta-mediated transcription by nuclear factor kappaB. Biochem. J. 2000; 348 (Pt 3): 591-6.
36. Alcolado R, Arthur MJ, Iredale JP. Pathogenesis of liver fibrosis. Clin. Sci. (Lond). 1997; 92: 103-12.
37. Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem. Biophys. Res. Commun. 2004; 315: 187-95.
38. Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin. Liver Dis. 2001; 21: 437-51.